Cable Hill Partners’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Cable Hill Partners’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-93,000	Closed	-$11K	–	858
2018 Q4	$11K	Buy	93,000 +59,506	+178%	+$39K	﹤0.01%	442
2018 Q3	$51K	Buy	33,494 +10,000	+43%	+$17.9K	0.02%	183
2018 Q2	$41K	Buy	23,494 +5,000	+27%	+$8.64K	0.02%	230
2018 Q1	$35K	Buy	18,494 +3,000	+19%	+$6.34K	0.02%	248
2017 Q4	$38K	Buy	15,494 +8,494	+121%	+$21.1K	0.02%	275
2017 Q3	$20K	Buy	7,000 +6,000	+600%	+$20.5K	0.01%	410
2017 Q2	$5K	Buy	+1,000	New	+$4.12K	﹤0.01%	576

Other funds holding SGYP

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Cable Hill Partners's SGYP Position: Q1 2019 in Review

Cable Hill Partners sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 93,000 shares — an estimated $11K sold.

Cable Hill Partners first reported a position in SGYP in Q2 2017 and held it in 7 quarters. The position peaked at $51K in Q3 2018. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

Cable Hill Partners reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
Cable Hill Partners sold 93,000 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $11K.
Cable Hill Partners first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2017 and held it in 7 quarters.
Cable Hill Partners's Synergy Pharmaceuticals, Inc Common Stock position peaked at $51K in Q3 2018.
12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on Cable Hill Partners's 13F filing for Q1 2019, filed 10 May 2019.